Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDX NASDAQ:ENTA NASDAQ:GHRS NASDAQ:MLTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$6.05$6.11$3.49▼$8.40$1.49B0.583.18 million shs9.84 million shsENTAEnanta Pharmaceuticals$12.66$13.34$6.43▼$17.15$368.13M0.97190,006 shs254,121 shsGHRSGH Research$22.24$20.86$11.32▼$25.94$1.53B1.31250,412 shs544,602 shsMLTXMoonLake Immunotherapeutics$19.21$17.96$5.95▼$62.75$1.41B1.04729,907 shs773,197 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx+3.60%+4.49%-0.66%+13.94%+67.59%ENTAEnanta Pharmaceuticals+0.16%+9.99%-7.99%+1.20%+75.10%GHRSGH Research+2.49%+7.88%+1.37%+59.20%+87.84%MLTXMoonLake Immunotherapeutics+0.10%+8.23%+17.35%+18.07%-55.84%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$6.05$6.11$3.49▼$8.40$1.49B0.583.18 million shs9.84 million shsENTAEnanta Pharmaceuticals$12.66$13.34$6.43▼$17.15$368.13M0.97190,006 shs254,121 shsGHRSGH Research$22.24$20.86$11.32▼$25.94$1.53B1.31250,412 shs544,602 shsMLTXMoonLake Immunotherapeutics$19.21$17.96$5.95▼$62.75$1.41B1.04729,907 shs773,197 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx+3.60%+4.49%-0.66%+13.94%+67.59%ENTAEnanta Pharmaceuticals+0.16%+9.99%-7.99%+1.20%+75.10%GHRSGH Research+2.49%+7.88%+1.37%+59.20%+87.84%MLTXMoonLake Immunotherapeutics+0.10%+8.23%+17.35%+18.07%-55.84%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDXArdelyx 2.91Moderate Buy$15.73159.95% UpsideENTAEnanta Pharmaceuticals 2.75Moderate Buy$20.2960.23% UpsideGHRSGH Research 2.73Moderate Buy$40.3881.54% UpsideMLTXMoonLake Immunotherapeutics 2.38Hold$23.8524.13% UpsideCurrent Analyst Ratings BreakdownLatest ENTA, ARDX, MLTX, and GHRS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2026ARDXArdelyx LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$16.006/9/2026MLTXMoonLake Immunotherapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.006/8/2026MLTXMoonLake Immunotherapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.005/19/2026GHRSGH Research HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$70.00 ➝ $65.005/15/2026GHRSGH Research CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/15/2026GHRSGH Research Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$25.00 ➝ $35.005/15/2026GHRSGH Research Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$42.00 ➝ $39.005/12/2026MLTXMoonLake Immunotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/12/2026MLTXMoonLake Immunotherapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$25.00 ➝ $30.005/11/2026MLTXMoonLake Immunotherapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$40.00 ➝ $45.004/21/2026GHRSGH Research Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDXArdelyx$407.32M3.67N/AN/A$0.69 per share8.77ENTAEnanta Pharmaceuticals$65.32M5.64N/AN/A$3.03 per share4.18GHRSGH ResearchN/AN/AN/AN/A$4.51 per shareN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$4.27 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDXArdelyx-$61.60M-$0.23N/A10.80N/A-13.58%-38.11%-11.85%8/3/2026 (Estimated)ENTAEnanta Pharmaceuticals-$81.89M-$2.59N/AN/AN/A-89.56%-64.04%-20.22%8/10/2026 (Confirmed)GHRSGH Research-$48.26M-$0.92N/AN/AN/AN/A-19.36%-18.73%8/6/2026 (Estimated)MLTXMoonLake Immunotherapeutics-$227.32M-$3.87N/AN/AN/AN/A-85.15%-60.52%8/4/2026 (Estimated)Latest ENTA, ARDX, MLTX, and GHRS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026GHRSGH Research-$0.27-$0.31-$0.04-$0.31N/AN/A5/11/2026Q2 2026ENTAEnanta Pharmaceuticals-$0.46-$0.45+$0.01-$0.45$17.03 million$17.16 million5/11/2026Q1 2026MLTXMoonLake Immunotherapeutics-$0.91-$0.98-$0.07-$0.98N/AN/A4/30/2026Q1 2026ARDXArdelyx-$0.13-$0.15-$0.02-$0.15$92.78 million$94.47 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARDXArdelyxN/AN/AN/AN/AN/AENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/AGHRSGH ResearchN/AN/AN/AN/AN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDXArdelyx1.373.493.28ENTAEnanta PharmaceuticalsN/A3.843.84GHRSGH ResearchN/A34.1334.13MLTXMoonLake Immunotherapeutics0.398.608.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDXArdelyx58.92%ENTAEnanta Pharmaceuticals94.99%GHRSGH Research56.90%MLTXMoonLake Immunotherapeutics93.85%Insider OwnershipCompanyInsider OwnershipARDXArdelyx5.30%ENTAEnanta Pharmaceuticals11.48%GHRSGH Research41.60%MLTXMoonLake Immunotherapeutics12.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDXArdelyx90247.03 million233.94 millionOptionableENTAEnanta Pharmaceuticals16029.08 million25.74 millionOptionableGHRSGH Research1068.61 million40.07 millionOptionableMLTXMoonLake Immunotherapeutics273.61 million64.77 millionOptionableENTA, ARDX, MLTX, and GHRS HeadlinesRecent News About These CompaniesMLTX stock moves higher as traders position for late-stage trial catalystsJune 18 at 3:00 PM | msn.comKristian Reich Sells 50,000 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) StockJune 18 at 7:33 AM | insidertrades.comMoonLake Immunotherapeutics $MLTX Shares Bought by Cormorant Asset Management LPJune 18 at 5:00 AM | marketbeat.comMoonLake Immunotherapeutics $MLTX Shares Bought by Rhenman & Partners Asset Management ABJune 13, 2026 | marketbeat.comMoonLake Immunotherapeutics $MLTX Shares Purchased by Fox Run Management L.L.C.June 11, 2026 | marketbeat.comMoonLake shareholders back director, auditor and compensation plansJune 9, 2026 | tipranks.comWhy did MLTX stock rise after-hours today?June 8, 2026 | msn.comMoonLake’s Phase 3 Sonelokimab Trial Reaches Completion in Hidradenitis SuppurativaJune 8, 2026 | tipranks.comMoonLake Immunotherapeutics (MLTX) Price Target Raised to $45 At H.C. Wainwright on FDA ProgressJune 2, 2026 | insidermonkey.comMoonLake Immunotherapeutics (MLTX) Price Target Raised to $45 At H.C. Wainwright on FDA ProgressJune 2, 2026 | finance.yahoo.comMoonLake Secures Long-Term Manufacturing Capacity with Vetter PharmaJune 1, 2026 | tipranks.com5 Best Immunology Stocks to Buy According to Hedge FundsMay 31, 2026 | insidermonkey.comUBS Group AG Has $3.15 Million Stake in MoonLake Immunotherapeutics $MLTXMay 25, 2026 | marketbeat.comGSA Capital Partners LLP Takes Position in MoonLake Immunotherapeutics $MLTXMay 22, 2026 | marketbeat.com187,600 Shares in MoonLake Immunotherapeutics $MLTX Purchased by Eagle Health Investments LPMay 21, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), MoonLake Immunotherapeutics (MLTX) and Dogwood Therapeutics (DWTX)May 20, 2026 | theglobeandmail.comMoonLake Immunotherapeutics Class A MLTXMay 20, 2026 | morningstar.comMLifeSci Capital Sticks to Their Buy Rating for MoonLake Immunotherapeutics (MLTX)May 17, 2026 | theglobeandmail.comMoonLake Immunotherapeutics: Buy Rating Reiterated on De-Risked Path to 2026 BLA and Robust SLK Data; $30 Price Target MaintainedMay 12, 2026 | tipranks.comMoonLake (MLTX) shares gain after positive FDA meeting on sonelokimab filingMay 11, 2026 | msn.comMoonLake Clears A Key Regulatory Hurdle, And Shares RocketMay 11, 2026 | investors.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesDrone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked NameBy Leo Miller | June 1, 2026Rocket Lab Is Down 24% From Its 52-Week High—Pullback or Problem?By Ryan Hasson | June 4, 20262 Software Stocks Turning AI Fears Into Fundamental GainsBy Dan Schmidt | May 21, 2026Intel Is the Market's Most Mispriced AI HedgeBy Jeffrey Neal Johnson | June 10, 20263 Dividend Kings That Earn Their Crown Every QuarterBy Chris Markoch | May 31, 2026ENTA, ARDX, MLTX, and GHRS Company DescriptionsArdelyx NASDAQ:ARDX$6.05 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$6.06 +0.01 (+0.17%) As of 06/18/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Enanta Pharmaceuticals NASDAQ:ENTA$12.66 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$12.66 0.00 (0.00%) As of 06/18/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.GH Research NASDAQ:GHRS$22.24 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$22.25 +0.01 (+0.05%) As of 06/18/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.MoonLake Immunotherapeutics NASDAQ:MLTX$19.21 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$19.23 +0.02 (+0.08%) As of 06/18/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate VMware: Broadcom's Second Biggest Business Set to Accelerate American Eagle’s Q1 Beat Leaves Investors With a Bigger Question Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
